← All trials
NCT06853496
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 13, 2025
- Primary completion
- Mar 31, 2027
- Completion date
- Mar 31, 2027
- First posted
- Mar 3, 2025
- Last posted
- Jul 29, 2025
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Japanese Foundation for Cancer ResearchLead sponsor
- Japan Agency for Medical Research and DevelopmentCollaborator
- Japanese Foundation for Cancer ResearchSponsor investigator
- The Cancer Institute Hospital of JFCROfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.